Close
CDMO Safety Testing 2026
Novotech

Articles

Auditory Therapy, Ototoxicity and GLP Compliance Will the promising market for ear disorder treatments follow ophthalmologyโ€™s dramatic growth curve?

The numbers are daunting โ€“ 15% of the global population suffers from hearing loss, including a significant number of children, teenagers, and the elderly. Hearing loss presents a growing public health problem, due to ageing and an urban way...

Direct-to-Patient Solutions Assuring Patient Participation and Retention in Clinical Trials

The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study ofย Drug Development. This is a rise of 145%, adjusted for inflation, compared to just...

Asiaโ€™s increasing levels of clinical trial industry competition are to your benefit

Biotechnology and pharmaceuticalย companies within the United States andย Europe face an increasing number ofย hurdles when undertaking clinical trialsย within their own country or region;ย problems such as over saturated patientย pools, difficulties meeting andย maintaining enrollment numbers,ย increasing costs and lengthy time delays. While clinical trials...

Time for a Different Approach to Quality Systems in Biopharmaceutical Manufacturing

Despite the wide array of information systems available for biopharmaceutical manufacturing, we need to adopt a โ€œfollow-the-workflowโ€ approach to overcome the process inefficiencies generated by quality and production silos. For the better part of thirty years, a critical component of...

New centre is tackling manufacturing challenge of cell therapy field

Stem cell science has made huge progress since the early 1960s when Canadian researchers James Till and Ernest McCulloch discovered blood stem cells and advanced medical research across the globe. Today, the Alliance for Regenerative Medicine estimates there are more...

Nativisโ€™ platform aims to transform disease treatment on a global scale โ€“ โ€œa symphony of curesโ€

In late 2015, I was approached by the board of Nativis, Inc.to take on the leadership of the company, by then a 13-year-old โ€œstartup.โ€ I had already been on the board of directors for over two years and through first-hand...

Rivaroxaban plus aspirin improves outcomes in stable cardiovascular disease (COMPASS)

Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line โ€“ LBCT Session at ESC...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป